ICON PLC
ICLRNASDAQTrading Snapshot
- Day Range
- $168.09 – $170.77
- 52-Week Range
- $66.57 – $203.91
- Volume
- $5.02B
- Avg Volume
- $4.09B
- Shares Outstanding
- 76.6M
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $8.25B
- Last Q Revenue
- $2.06B
- P/E Ratio
- 40.2
- P/S Ratio
- 1.6x
- EPS (TTM)
- $4.28
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −4.0%
Why Investors Own ICLR
- ✓High-growth profile — revenue up -9.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ICON PLC
ICLR
StockOtter · stockotter.spaceAbout ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
WINTON GROUP Ltd Has $313,000 Holdings in Icon Plc $ICLR
WINTON GROUP Ltd cut its stake in Icon Plc (NASDAQ: ICLR) by 94.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,800 shar
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock?
A Look at Icon PLC (ICLR) After 3.2% Gain -- GF Value $208.22 vs Price $172.49
On August 19, 2026, Icon PLC (ICLR) shares rose 3.2% today, closing at $172.49, which is within its 52-week range of $66.57 to $203.91. This recent uptick in sh
Icon PLC (ICLR) Shares Surge 3.9% -- What GF Score of 93 Tells Investors
On August 17, 2026, Icon PLC (ICLR) shares rose 3.9%, bringing the current price to $169.45. This price is situated within a 52-week range of $66.57 to $203.91,
Oakmark Concentrated Strategy Q2 2026 Performance Review
The portfolio's return was 9.21% (net) for the reporting period. Centene, ICON and Keurig Dr Pepper were the contributors during the quarter. Intercontinental Exchange, Salesforce and ConocoPhillips were the detractors d
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.